NORWALK, Conn. Healthcare market research company IMS Health announced Monday the availability of a new analytical product for the specialty channel, IMS Specialty Market Dynamics.
IMS said the product, part of its IMS Specialty Solutions portfolio of information products, contains “unprecedented insights” into the dynamics of the specialty channel allowing for identification of trends and growth opportunities related to utilization, product switching, compliance, product usage by indication and other information.
Sales of pharmaceutical and biotech drugs used in specialty pharmacies to treat such chronic, complex conditions as HIV, cancer and psoriasis are expected to exceed $160 billion by 2013, according to the company.
“This marks a significant advance for our clients that offer specialty medications, all of whom share a vital interest in a market segment that’s growing at twice the pace of traditional pharmaceutical products,” IMS general manager for specialty offerings development Pam Sauerwald said. “As demand for evidence-based information in the specialty sector grows, we’re uniquely positioned to provide a deeper understanding into how these products are used – helping clients to adjust portfolio strategies and improve their commercial effectiveness.”